George Wilding

Q: What Schools Are Affiliated With George Wilding

George Wilding is affiliated with the following schools: Saitama Medical University, Indiana University, MD Anderson Cancer Center, Hannover Medical School, University of Wisconsin–Madison, Marmara University, Pennsylvania State University, University of Chicago

George Wilding's AcademicInfluence.com Rankings

George Wilding

Philosophy

#9047

World Rank

#12544

Historical Rank

Logic

#6048

World Rank

#7527

Historical Rank

philosophy Degrees

Download Badge

Philosophy

George Wilding's Degrees

Bachelors Biology University of California, Berkeley
Doctorate Medicine Stanford University

Similar Degrees You Can Earn

Best Online Bachelor's in Biology

Why Is George Wilding Influential?

(Suggest an Edit or Addition)

(See a Problem?)

George Wilding's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma (2009) (2096)
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. (2008) (2023)
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. (2006) (1646)
Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. (1999) (1024)
Sunitinib in patients with metastatic renal cell carcinoma. (2006) (965)
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. (2016) (889)
Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. (2006) (873)
Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. (1998) (870)
Therapy-induced senescence in cancer. (2010) (594)
The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. (2013) (482)
Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial (2016) (477)
Intermittent versus continuous androgen deprivation in prostate cancer. (2013) (471)
Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. (2005) (469)
Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. (2007) (433)
Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). (2006) (429)
DNA fluorometric assay in 96-well tissue culture plates using Hoechst 33258 after cell lysis by freezing in distilled water. (1990) (399)
Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. (2009) (328)
Prooxidant-antioxidant shift induced by androgen treatment of human prostate carcinoma cells. (1997) (311)
Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. (2003) (288)
Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. (2012) (263)
Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study. (2005) (258)
Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. (2000) (250)
A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. (2006) (249)
Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group. (2004) (247)
Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors. (2003) (243)
Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA70, in human prostate cancer DU145 cells. (1998) (219)
Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer. (2009) (217)
Beta-lapachone-mediated apoptosis in human promyelocytic leukemia (HL-60) and human prostate cancer cells: a p53-independent response. (1995) (213)
Aberrant response in vitro of hormone‐responsive prostate cancer cells to antiandrogens (1989) (212)
Phase II Study of Dasatinib in Patients with Metastatic Castration-Resistant Prostate Cancer (2009) (208)
Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. (2004) (201)
Sunitinib efficacy against advanced renal cell carcinoma. (2007) (201)
Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. (2013) (197)
Activity of second‐line chemotherapy in docetaxel‐refractory hormone‐refractory prostate cancer patients (2007) (196)
Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916. (2009) (183)
Engineering a Prostate-Specific Membrane Antigen–Activated Tumor Endothelial Cell Prodrug for Cancer Therapy (2012) (182)
Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: an attempt at modulation of glutathione. (1994) (180)
Differential effects of transforming growth factor β on human prostate cancer cells in vitro (1989) (171)
A Phase II Multicenter, Randomized, Double-Blind, Safety Trial Assessing the Pharmacokinetics, Pharmacodynamics, and Efficacy of Oral 2-Methoxyestradiol Capsules in Hormone-Refractory Prostate Cancer (2005) (170)
Phase I study of continuous-infusion L-S,R-buthionine sulfoximine with intravenous melphalan. (1997) (168)
An Open-Label, Multicenter, Phase I/II Study of Single-Agent AT-101 in Men with Castrate-Resistant Prostate Cancer (2009) (167)
A Phase I Trial of Perifosine (NSC 639966) on a Loading Dose/Maintenance Dose Schedule in Patients with Advanced Cancer (2004) (166)
AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a Phase 2 study of cytokine-refractory, metastatic renal cell cancer (RCC) (2005) (163)
Taxol in advanced, hormone‐refractory carcinoma of the prostate. A phase II trial of the eastern cooperative oncology group (1993) (158)
Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium (2004) (158)
Endocrine control of prostate cancer. (1995) (150)
Phase I Trial of a Monoclonal Antibody Specific for αvβ3 Integrin (MEDI-522) in Patients with Advanced Malignancies, Including an Assessment of Effect on Tumor Perfusion (2005) (149)
Volociximab, a Chimeric Monoclonal Antibody that Specifically Binds α5β1 Integrin: A Phase I, Pharmacokinetic, and Biological Correlative Study (2008) (146)
Role of transforming growth factor ‐α in human prostate cancer cell growth (1989) (145)
Protein kinase Cepsilon interacts with signal transducers and activators of transcription 3 (Stat3), phosphorylates Stat3Ser727, and regulates its constitutive activation in prostate cancer. (2007) (135)
Vorinostat (NSC# 701852) in Patients with Relapsed Non-small Cell Lung Cancer: A Wisconsin Oncology Network Phase II Study (2009) (131)
Transforming growth factor beta 1 induces cachexia and systemic fibrosis without an antitumor effect in nude mice. (1991) (128)
Axitinib in Metastatic Renal Cell Carcinoma: Results of a Pharmacokinetic and Pharmacodynamic Analysis (2013) (128)
Phase 2 trials of SU11248 show antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma (RCC) (2005) (124)
Pilot trial of interleukin-2 and zoledronic acid to augment γδ T cells as treatment for patients with refractory renal cell carcinoma (2011) (122)
Transforming growth factors type β1 and β2 are equipotent growth inhibitors of human breast cancer cell lines (1989) (120)
Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol (2002) (120)
Phase 2 trial of sorafenib in patients with advanced urothelial cancer (2009) (117)
A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802 (2012) (116)
Phase I Trial of 2-Methoxyestradiol NanoCrystal Dispersion in Advanced Solid Malignancies (2009) (114)
Phase I clinical trial of perillyl alcohol administered daily. (1998) (109)
Effect of antioxidants on androgen-induced AP-1 and NF-kappaB DNA-binding activity in prostate carcinoma cells. (1999) (102)
Phase II study of paclitaxel plus gemcitabine in refractory germ cell tumors (E9897): a trial of the Eastern Cooperative Oncology Group. (2002) (102)
Improved overall survival trends of men with newly diagnosed M1 prostate cancer: a SWOG phase III trial experience (S8494, S8894 and S9346). (2012) (96)
Phase I clinical and pharmacokinetic study of perillyl alcohol administered four times a day. (2000) (96)
A Phase I and Pharmacokinetic Study of Oral Lapatinib Administered Once or Twice Daily in Patients with Solid Malignancies (2009) (92)
Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer. (2011) (91)
Phase I trial of tremelimumab in combination with short-term androgen deprivation in patients with PSA-recurrent prostate cancer (2012) (90)
The importance of steroid hormones in prostate cancer. (1992) (89)
Effects of steroid hormones and peptide growth factors on protooncogene c-fos expression in human breast cancer cells. (1988) (89)
A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC) (2011) (87)
Randomized Phase I Chemoprevention Dose-Seeking Study of α-Difluoromethylornithine (1993) (85)
Tissue examination to monitor antiangiogenic therapy: a phase I clinical trial with endostatin. (2001) (85)
Axitinib (AG-013736; AG) in patients (pts) with metastatic renal cell cancer (RCC) refractory to sorafenib (2007) (83)
Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors (2011) (81)
Phase II study of paclitaxel plus carboplatin in patients with advanced carcinoma of the urothelium and renal dysfunction (E2896) (2002) (80)
SU011248, a novel tyrosine kinase inhibitor, shows antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma: Results of a phase 2 trial. (2004) (79)
Increase in gamma-glutamylcysteine synthetase activity and steady-state messenger RNA levels in melphalan-resistant DU-145 human prostate carcinoma cells expressing elevated glutathione levels. (1992) (75)
Phase 2 trial of epothilone B analog BMS‐247550 (ixabepilone) in advanced carcinoma of the urothelium (E3800) (2007) (74)
A phase II study of 2-methoxyestradiol nanocrystal colloidal dispersion alone and in combination with sunitinib malate in patients with metastatic renal cell carcinoma progressing on sunitinib malate (2012) (74)
A phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancer (2013) (74)
A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors. (2011) (74)
A Phase II Trial of Flavopiridol (NSC #649890) in Patients with Previously Untreated Metastatic Androgen-Independent Prostate Cancer (2004) (70)
v-rasH expression confers hormone-independent in vitro growth to LNCaP prostate carcinoma cells. (1991) (68)
Response of prostate cancer cells to peptide growth factors: transforming growth factor-beta. (1991) (68)
A phase II trial of gefitinib in patients with non‐metastatic hormone‐refractory prostate cancer (2007) (65)
Growth properties and tumorigenesis of MCF-7 cells transfected with isogenic mutants of rasH. (1990) (64)
A first in human study of SB-743921, a kinesin spindle protein inhibitor, to determine pharmacokinetics, biologic effects and establish a recommended phase II dose (2011) (61)
Phase I trial of sunitinib malate plus interferon-alpha for patients with metastatic renal cell carcinoma. (2009) (60)
A Phase I and Pharmacologic Trial of Two Schedules of the Proteasome Inhibitor, PS-341 (Bortezomib, Velcade), in Patients with Advanced Cancer (2005) (60)
Phase I trial of 1α-hydroxyvitamin D2 in patients with hormone refractory prostate cancer (2002) (59)
Phase II Study of 1α-Hydroxyvitamin D2 in the Treatment of Advanced Androgen-independent Prostate Cancer (2003) (59)
Overall survival (OS) and safety of dasatinib/docetaxel versus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC): Results from the randomized phase III READY trial. (2013) (57)
Intermittent (IAD) versus continuous androgen deprivation (CAD) in hormone sensitive metastatic prostate cancer (HSM1PC) patients (pts): Results of S9346 (INT-0162), an international phase III trial. (2012) (56)
Improvements in clinical benefit with vinorelbine in the treatment of hormone-refractory prostate cancer: a phase II trial. (1999) (56)
Activation of mitogen-activated protein kinase pathway by the antiandrogen hydroxyflutamide in androgen receptor-negative prostate cancer cells. (2002) (56)
Pharmacodynamic Study Using FLT PET/CT in Patients with Renal Cell Cancer and Other Solid Malignancies Treated with Sunitinib Malate (2011) (56)
Phase II trial of perillyl alcohol (NSC 641066) administered daily in patients with metastatic androgen independent prostate cancer (2003) (54)
A non-comparative randomized phase II study of 2 doses of ATN-224, a copper/zinc superoxide dismutase inhibitor, in patients with biochemically recurrent hormone-naïve prostate cancer. (2013) (53)
Phase I clinical and pharmacokinetic study of oral carboxyamidotriazole, a signal transduction inhibitor. (1997) (53)
Endothelin Receptor Antagonists in Cancer Therapy (2007) (52)
Androgen antagonist activity by the antioxidant moiety of vitamin E, 2,2,5,7,8-pentamethyl-6-chromanol in human prostate carcinoma cells. (2003) (51)
Randomized, Double-Blinded Phase II Evaluation of Docetaxel with or without Doxercalciferol in Patients with Metastatic, Androgen-Independent Prostate Cancer (2008) (51)
Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study. (2007) (50)
Diastolic blood pressure (dBP) and pharmacokinetics (PK) as predictors of axitinib efficacy in metastatic renal cell cancer (mRCC). (2009) (50)
First-in-human trial of a poly(ADP)-ribose polymerase (PARP) inhibitor MK-4827 in advanced cancer patients with antitumor activity in BRCA-deficient tumors and sporadic ovarian cancers (soc). (2010) (49)
Disruption of cellular energy balance by suramin in intact human prostatic carcinoma cells, a likely antiproliferative mechanism. (1991) (49)
JunD mediates androgen‐induced oxidative stress in androgen dependent LNCaP human prostate cancer cells (2008) (48)
Initial results from ASSURE (E2805): Adjuvant sorafenib or sunitinib for unfavorable renal carcinoma, an ECOG-ACRIN-led, NCTN phase III trial. (2015) (48)
A phase I study of AT-101 with cisplatin and etoposide in patients with advanced solid tumors with an expanded cohort in extensive-stage small cell lung cancer (2014) (47)
Concentration-dependent effects of fatty acids on warfarin binding to albumin. (1977) (46)
Clinical activity of GW572016 in EGF10003 in patients with solid tumors. (2004) (45)
A phase I trial of MK-0731, a Kinesin Spindle Protein (KSP) inhibitor, in patients with solid tumors (2012) (45)
Induction of AP‐1 activity by androgen activation of the androgen receptor in LNCaP human prostate carcinoma cells (2005) (45)
Randomized phase II multicenter study of the efficacy and safety of sunitinib on the 4/2 versus continuous dosing schedule as first-line therapy of metastatic renal cell carcinoma: Renal EFFECT Trial. (2011) (45)
Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B 9480. (2002) (44)
A national multicenter phase 2 study of prostate-specific antigen (PSA) pox virus vaccine with sequential androgen ablation therapy in patients with PSA progression: ECOG 9802. (2015) (44)
Population pharmacokinetics of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (Triapine®) in cancer patients (2011) (43)
Randomized prospective phase III trial of difluoromethylornithine vs placebo in preventing recurrence of completely resected low risk superficial bladder cancer. (2005) (42)
Effects of Adjuvant Sorafenib and Sunitinib on Cardiac Function in Renal Cell Carcinoma Patients without Overt Metastases: Results from ASSURE, ECOG 2805 (2015) (42)
A Phase I study of intermittently dosed vorinostat in combination with bortezomib in patients with advanced solid tumors (2013) (41)
Sequential axitinib (AG-013736) therapy of patients (pts) with metastatic clear cell renal cell cancer (RCC) refractory to sunitinib and sorafenib, cytokines and sorafenib, or sorafenib alone (2008) (41)
Alteration of glyceraldehyde-3-phosphate dehydrogenase activity and messenger RNA content by androgen in human prostate carcinoma cells. (1995) (40)
Real-Time Immune Monitoring to Guide Plasmid DNA Vaccination Schedule Targeting Prostatic Acid Phosphatase in Patients with Castration-Resistant Prostate Cancer (2014) (40)
Phase II trial of oral piritrexim in advanced, previously treated transitional cell cancer of bladder (2004) (40)
Randomized phase I chemoprevention dose-seeking study of alpha-difluoromethylornithine. (1993) (40)
Phase II trial of gemcitabine and docetaxel in patients with advanced carcinoma of the urothelium (2003) (39)
Results from a pilot Phase I trial of gefitinib combined with docetaxel and estramustine in patients with hormone‐refractory prostate cancer (2006) (38)
Phase I Dose-Escalation Study of the Novel Antiandrogen BMS-641988 in Patients with Castration-Resistant Prostate Cancer (2010) (38)
A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer (2016) (38)
Leinamycin E1 acting as an anticancer prodrug activated by reactive oxygen species (2015) (37)
Clinical and immunological effects of granulocyte-macrophage colony-stimulating factor coadministered with interleukin 2: a phase IB study. (1996) (37)
A small molecule polyamine oxidase inhibitor blocks androgen-induced oxidative stress and delays prostate cancer progression in the transgenic adenocarcinoma of the mouse prostate model. (2009) (36)
Phase I and Pharmacokinetic Study of Prinomastat, a Matrix Metalloprotease Inhibitor (2004) (36)
Quality of life impact of three different doses of suramin in patients with metastatic hormone‐refractory prostate carcinoma (2004) (36)
Phase II open label, multi‐center clinical trial of modulation of intermediate endpoint biomarkers by 1α‐hydroxyvitamin D2 in patients with clinically localized prostate cancer and high grade pin (2013) (36)
Expression of spermidine/spermine N1‐acetyl transferase (SSAT) in human prostate tissues is related to prostate cancer progression and metastasis (2015) (35)
Androgen receptor requires JunD as a coactivator to switch on an oxidative stress generation pathway in prostate cancer cells. (2010) (34)
Transforming growth factors type beta 1 and beta 2 are equipotent growth inhibitors of human breast cancer cell lines. (1989) (33)
362 First in human trial of a poly(ADP)-ribose polymerase (PARP) inhibitor MK-4827 in advanced cancer patients (p) with antitumor activity in BRCA-deficient and sporadic ovarian cancers (2010) (32)
Growth inhibition and differentiation in human prostate carcinoma cells induced by the vitamin D analog 1α,24‐dihydroxyvitamin D2 (2003) (32)
A phase I study of gemcitabine, 5-fluorouracil and leucovorin in patients with advanced, recurrent, and/or metastatic solid tumors (1998) (32)
Piritrexim in Advanced, Refractory Carcinoma of the Urothelium (E3896): A Phase II Trial of the Eastern Cooperative Oncology Group (2002) (32)
Suramin‐induced weakness from hypophosphatemia and mitochondrial myopathy. Association of suramin with mitochondrial toxicity in humans (1994) (31)
Electron paramagnetic resonance study of peripheral blood mononuclear cells from patients with refractory solid tumors treated with Triapine. (2008) (30)
A phase I study of Triapine® in combination with doxorubicin in patients with advanced solid tumors (2009) (30)
Drug development in prostate cancer. (1999) (30)
Phase II Clinical Trial Design: Methods in Translational Research from the Genitourinary Committee at the Eastern Cooperative Oncology Group (2006) (30)
Dasatinib in patients with hormone-refractory progressive prostate cancer: A phase II study (2008) (30)
A phase I trial of perillyl alcohol administered four times daily for 14 days out of 28 days (2004) (30)
Effects of Interferon βser and Transforming Growth Factor β on Prostatic Cell Lines (1991) (29)
Characteristics of the glutathione/glutathione-S-transferase detoxification system in melphalan resistant human prostate cancer cells. (1993) (29)
Effects of a monoclonal anti-αvβ3 integrin antibody on blood vessels—A pharmacodynamic study (2006) (28)
Newer therapies in advanced prostate cancer. (2004) (28)
Prostate cancer prevention strategies using antiproliferative or differentiating agents. (2001) (28)
Phase I trial of perillyl alcohol administered four times daily continuously (2003) (27)
Department of Defense prostate cancer clinical trials consortium: a new instrument for prostate cancer clinical research. (2009) (27)
The treatment of metastatic renal cell carcinoma patients with recombinant human gamma interferon. (1998) (27)
A phase I study of vorinostat in combination with bortezomib in patients with advanced malignancies (2013) (26)
Prostate cancer prevention agent development: Criteria and pipeline for candidate chemoprevention agents. (2001) (26)
Clinical Trial Characteristics and Barriers to Participant Accrual: The MD Anderson Cancer Center Experience over 30 years, a Historical Foundation for Trial Improvement (2017) (26)
Phase I study using continuous intravenous (CI) KOS-862 (Epothilone D) in patients with solid tumors. (2004) (26)
Safety and preliminary efficacy analysis of the mTOR inhibitor ridaforolimus in patients with taxane-treated, castration-resistant prostate cancer. (2012) (26)
A phase I study of zibotentan (ZD4054) in patients with metastatic, castrate-resistant prostate cancer (2011) (25)
Angiogenesis Inhibitors (2000) (24)
Amongst eligible patients, age and comorbidity do not predict for dose-limiting toxicity from phase I chemotherapy (2010) (24)
Eastern Cooperative Oncology Group Phase II Trial of lapatinib in men with biochemically relapsed, androgen dependent prostate cancer. (2013) (24)
Reduced warfarin binding of albumin variants. (1977) (24)
Cyclopropane-containing polyamine analogues are efficient growth inhibitors of a human prostate tumor xenograft in nude mice. (2003) (24)
Phase I trial of 1alpha-hydroxyvitamin d(2) in patients with hormone refractory prostate cancer. (2002) (24)
Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for cancer therapy (Science Translational Medicine) (2012) (23)
IMMEDIATE HORMONAL THERAPY VS. OBSERVATION FOR NODE POSITIVE PROSTATE CANCER FOLLOWING RADICAL PROSTATECTOMY AND PELVIC LYMPHADENECTOMY: A RANDOMIZED PHASE III EASTERN COOPERATIVE ONCOLOGY GROUP/INTER GROUP TRIAL (1999) (23)
Phase II study of 1alpha-hydroxyvitamin D(2) in the treatment of advanced androgen-independent prostate cancer. (2003) (22)
Phase 2 trial of pemetrexed disodium and gemcitabine in advanced urothelial cancer (E4802) (2008) (22)
Continuous 28-day iododeoxyuridine infusion and hyperfractionated accelerated radiotherapy for malignant glioma: a phase I clinical study. (2004) (22)
A pilot trial of chemohormonal therapy for metastatic prostate carcinoma (1992) (22)
Effects of a monoclonal anti-alphavbeta3 integrin antibody on blood vessels - a pharmacodynamic study. (2007) (21)
Executive Summary of the National Cancer Institute Workshop: Highlights and recommendations. (2001) (21)
Phase I clinical and pharmacokinetic study of an one-hour infusion of ormaplatin (NSC 363812) (2004) (20)
Phase I and pharmacokinetic study of a micronized formulation of carboxyamidotriazole, a calcium signal transduction inhibitor: toxicity, bioavailability and the effect of food. (2002) (20)
Phase I clinical and pharmacokinetic study of NSC 655649, a rebeccamycin analogue, given in both single-dose and multiple-dose formats. (2002) (20)
Low-dose difluoromethylornithine and polyamine levels in human prostate tissue. (1999) (19)
A Phase I Pharmacokinetic and Pharmacodynamic Correlative Study of the Antisense Bcl-2 Oligonucleotide G3139, in Combination with Carboplatin and Paclitaxel, in Patients with Advanced Solid Tumors (2008) (19)
Genetic control of interindividual variations in racemic warfarin binding to plasma and albumin of twins (1977) (19)
A phase I study of BMS-582664 (brivanib alaninate), an oral dual inhibitor of VEGFR and FGFR tyrosine kinases, in patients (pts) with advanced/metastatic solid tumors: Safety, pharmacokinetic (PK), and pharmacodynamic (PD) findings (2007) (19)
Phase II study of carboxyamidotriazole in patients with advanced renal cell carcinoma refractory to immunotherapy (2005) (19)
Role of transforming growth factor-alpha in human prostate cancer cell growth. (1989) (19)
Effects of suramin on the proliferation of primary epithelial cell cultures derived from normal, benign hyperplastic and cancerous human prostates (1993) (19)
Phase II trial of weekly ixabepilone in men with metastatic castrate-resistant prostate cancer (E3803): a trial of the Eastern Cooperative Oncology Group. (2012) (19)
A Phase Ib/II trial of granulocyte‐macrophage−colony stimulating factor and interleukin‐2 for renal cell carcinoma patients with pulmonary metastases (2000) (19)
Effect of Renal Impairment on the Pharmacokinetics and Safety of Axitinib (2016) (18)
Phase I clinical and pharmacokinetic trial of irofulven (2001) (18)
A randomized phase II trial of mitoxantrone, estramustine and vinorelbine or bcl-2 modulation with 13-cis retinoic acid, interferon and paclitaxel in patients with metastatic castrate-resistant prostate cancer: ECOG 3899 (2010) (18)
Effects of the polyamine analogues BE-4-4-4-4, BE-3-7-3, and BE-3-3-3 on the proliferation of three prostate cancer cell lines (1997) (18)
Alteration in gamma-glutamyl transpeptidase activity and messenger RNA of human prostate carcinoma cells by androgen. (1997) (18)
A phase I pharmacodynamic trial of bortezomib in combination with doxorubicin in patients with advanced cancer (2008) (18)
Phase I trial of novel kinesin spindle protein (KSP) inhibitor SB-715992 IV Q 21 days (2004) (17)
Evaluation of RU58841 as an anti-androgen in prostate PC3 cells and a topical anti-alopecia agent in the bald scalp of stumptailed macaques (1998) (17)
The maximum tolerated dose and biologic effects of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) in combination with irinotecan for patients with refractory solid tumors (2010) (17)
A Phase II Study of 13-cis Retinoic Acid Plus Interferon α-2a in Advanced Stage Penile Carcinoma: An Eastern Cooperative Oncology Group Study (E3893) (2003) (17)
Phase I trial of novel kinesin spindle protein (KSP) inhibitor SB-715992 IV Q 21 days. (2004) (16)
LHRH agonists and human breast cancer cells (1987) (16)
Evaluation of mRNA by Q-RTPCR and protein expression by AQUA of the M2 subunit of ribonucleotide reductase (RRM2) in human tumors (2009) (15)
Phase I Trial of Weekly Paclitaxel and BMS-214662 in Patients with Advanced Solid Tumors (2007) (15)
559 Pharmacokinetics of GW572016 in an ascending dose tolerability study of phase I cancer patients (2003) (15)
Phase II study of intravesical therapy with AD32 in patients with papillary urothelial carcinoma or carcinoma in situ (CIS) refractory to prior therapy with bacillus Calmette-Guerin (E3897): a trial of the Eastern Cooperative Oncology Group. (2009) (14)
A phase I study of SR-2508 and cyclophosphamide administered by intravenous injection. (1991) (14)
Phase I study of continuous MKC-1 in patients with advanced or metastatic solid malignancies using the modified Time-to-Event Continual Reassessment Method (TITE-CRM) dose escalation design (2012) (14)
Phase I Study of the Oral Histone Deacetylase Inhibitor SB939 In Patients with Advanced Hematologic Malignancies (2010) (14)
Phase I study to determine tolerability and pharmacokinetics (PK) of SB-743921, a novel kinesin spindle protein (KSP) inhibitor. (2005) (14)
A safety, tolerability, and pharmacokinetic (PK) study of GW572016 in patients with solid tumors (2004) (13)
A phase II study of once-daily dasatinib for patients with castration-resistant prostate cancer (CRPC) (CA180085). (2009) (13)
Phase I dose escalation study to determine the safety, pharmacokinetics and pharmacodynamics of BMS-582664, a VEGFR/FGFR inhibitor in patients with advanced/metastatic solid tumors. (2006) (13)
A dose escalation, safety, and tolerability study of MN-029 in patients with advanced solid tumors (2010) (13)
A Phase II Trial of Homoharringtonine and Caracemide in the Treatment of Patients with Advanced Large Bowel Cancer (1999) (13)
A phase I study of a DNA vaccine targeting prostatic Acid phosphatase in patients with stage D0 prostate cancer. (2005) (12)
Quantitation of β-lapachone and 3-hydroxy-β-lapachone in human plasma samples by reversed-phase high-performance liquid chromatography (1997) (12)
Angiogenesis inhibitors in genitourinary cancers. (2003) (12)
A randomized phase II trial evaluating different schedules of zoledronic acid on bone mineral density in patients with prostate cancer beginning androgen deprivation therapy. (2013) (12)
Disruption of mitochondrial function by suramin measured by rhodamine 123 retention and oxygen consumption in intact DU145 prostate carcinoma cells. (1992) (12)
4507 ORAL Axitinib (AG-013736; AG) in patients (pts) with metastatic clear cell renal cell cancer (RCC) refractory to sorafenib (2007) (11)
Extended culturing of androgen‐responsive human primary epithelial prostate cell isolates by continuous treatment with interstitial collagenase (1997) (11)
166 A phase I dose-escalation study of anti-a5β1 integrin monoclonal antibody (M200) in patients with refractory solid tumors (2004) (11)
Final results of the phase I trial of niraparib (MK4827), a poly(ADP)ribose polymerase (PARP) inhibitor incorporating proof of concept biomarker studies and expansion cohorts involving BRCA1/2 mutation carriers, sporadic ovarian, and castration resistant prostate cancer (CRPC). (2013) (11)
Sunitinib malate (SU) plus interferon (IFN) in first line metastatic renal cell cancer (mRCC): Results of a dose-finding study (2007) (11)
Targeting androgen receptor and JunD interaction for prevention of prostate cancer progression (2014) (11)
Phase I clinical and pharmacokinetic trial of penclomedine using a novel, two-stage trial design for patients with advanced malignancy. (1998) (11)
Pretreatment with anti-oxidants sensitizes oxidatively stressed human cancer cells to growth inhibitory effect of suberoylanilide hydroxamic acid (SAHA) (2011) (10)
Phase I Trial of the Polyamine Analog N1,N14-Diethylhomospermine (DEHSPM) in Patients with Advanced Solid Tumors (2004) (10)
Effect of medical castration on CYP3A4 enzyme activity using the erythromycin breath test (2008) (10)
A phase 1/1b study of satraplatin (JM-216) in combination with docetaxel in patients with advanced solid tumors and metastatic castrate-resistant prostate cancer. (2013) (10)
Inhibitor of p52 NF-κB subunit and androgen receptor (AR) interaction reduces growth of human prostate cancer cells by abrogating nuclear translocation of p52 and phosphorylated ARser81 (2015) (10)
Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study results (2011) (10)
Phase I clinical and pharmacokinetic (PK) trial of the kinesin spindle protein (KSP) inhibitor MK-0731 in cancer patients. (2006) (10)
Potential cytochrome P-450 drug-drug interactions in adults with metastatic solid tumors and effect on eligibility for Phase I clinical trials. (2015) (10)
Phase I clinical trial of fazarabine as a twenty-four-hour continuous infusion. (1991) (10)
Phase II study of interferon-alpha and doxycycline for advanced renal cell carcinoma (2006) (9)
Renal clearance, tissue distribution, and CA-125 responses in a phase I trial of suramin. (1998) (9)
Effect of PSA-tricom, a pox-viral vaccine in prostate cancer (PCa), on tumor growth rates within 80 days after initiation in nonmetastatic PCa. (2013) (9)
Effects of interferon beta ser and transforming growth factor beta on prostatic cell lines. (1991) (9)
Atrasentan in Patients With Advanced Renal Cell Carcinoma: A Phase 2 Trial of the ECOG-ACRIN Cancer Research Group (E6800). (2015) (9)
Phosphoinositide metabolism in human prostate cancer cells in vitro (1990) (9)
A phase I trial of gemcitabine in combination with patupilone in patients with advanced solid tumors (2008) (9)
Sunitinib in combination with docetaxel and prednisone in patients with metastatic hormone-refractory prostate cancer (mHRPC) - preliminary results (2008) (9)
Leucovorin modulation of 5-iododeoxyuridine radiosensitization: a phase I study. (1996) (9)
Prostate cancer cells survive anti‐androgen and mitochondrial metabolic inhibitors by modulating glycolysis and mitochondrial metabolic activities (2021) (8)
A phase I study of selumetinib (AZD6244/ARRY-142866) in combination with cetuximab (cet) in refractory solid tumors and KRAS mutant colorectal cancer (CRC). (2012) (8)
Efficacy of suramin against human prostate carcinoma DU145 xenografts in nude mice (1999) (8)
Survival of Patients Who Had Salvage Castration After Failure on Bicalutamide Monotherapy for Stage (D2) Prostate Cancer (2000) (8)
4505 ORAL A population pharmacokinetic/pharmacodynamic (PK/PD) analysis of exposure–response for sunitinib in metastatic renal cell carcinoma (mRCC) (2007) (7)
Dose-escalation study of fixed-dose rate gemcitabine combined with capecitabine in advanced solid malignancies (2009) (7)
Clinical and dynamic imaging results of the first phase I study of AG-013736, an oral anti-angiogenesis agent, in patients (pts) with advanced solid tumors. (2004) (7)
The cellular response of human breast cancer to estrogen. (1988) (7)
A phase I study of Topotecan, as a radiosensitizer, for thoracic malignancies. (2004) (7)
Cytotoxic Evaluation of 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone, 3-AP, in Peripheral Blood Lymphocytes of Patients with Refractory Solid Tumors using Electron Paramagnetic Resonance. (2011) (6)
Phase I trial of motexafin gadolinium and doxorubicin in the treatment of advanced malignancies (2011) (6)
Vorinostat in combination with bortezomib in patients with advanced malignancies directly alters transcription of target genes (2013) (6)
A multicenter phase 1/2a dose-escalation study of the antioxidant moiety of vitamin E 2,2,5,7,8-pentamethyl-6-chromanol (APC-100) in men with advanced prostate cancer (2016) (6)
Tolerability profile of ZD4054 is consistent with the effects of endothelin A receptor-specific antagonism (2005) (6)
A phase I study of 5-fluorouracil, leucovorin and levamisole (1997) (6)
Abstract B244: A first-in-human phase 1 clinical study of G-202, a thapsigargin-based Prostate-Specific Membrane Antigen (PSMA) activated prodrug, in patients with advanced solid tumors. (2013) (6)
Absolute PSA value after androgen deprivation (AD) is a strong independent predictor of survival in new metastatic (D2) prostate cancer (PCa): Data from Southwest Oncology Group Trial 9346 (INT-0162). (2006) (6)
A safety, tolerability, and pharmacokinetic (PK) study of GW572016 in patients with solid tumors. (2004) (5)
Period analysis of prostate cancer survival. (2005) (5)
Comparative efficacy of sunitinib administered on an intermittent or a continuous daily dosing schedule in metastatic renal cell carcinoma (mRCC) and gastrointestinal stromal tumor (GIST) patients predicted using population PK approaches (2008) (5)
Phase I clinical and pharmacokinetic study of oral penclomedine (NSC 338720) in adults with advanced solid malignancy. (2002) (4)
A phase I study of R-(-)-gossypol (AT-101) in combination with cisplatin (P) and etoposide (E) in patients with advanced solid tumors and extensive-stage small cell lung cancer (ES-SCLC). (2010) (4)
Sunitinib in combination with paclitaxel and carboplatin in patients with advanced solid tumors: Updated phase I study results. (2016) (4)
Phase I Study of Eniluracil, Oral 5-Fluororacil and Gemcitabine in Patients with Advanced Malignancy (2002) (4)
A phase II study of vinblastine in combination with acrivastine in patients with advanced renal cell carcinoma (2004) (4)
1455: Immediate VS Delayed Hormonal Therapy (HT) in Patients with Nodal Positive (N+) Prostate Cancer Who Had Undergone Radical Prostatectomy (RP) + Pelvic Lymphadenectomy (LND): Results of Central Pathology Review (CPR) (2004) (3)
Phase I dose-escalation trial of tremelimumab in combination with bicalutamide in patients with recurrent prostate cancer. (2011) (3)
9 Continuous 28 day iododeoxyuridine (IUdR) infusion and hyperfractionated accelerated radiotherapy (HART) for malignant glioma: A phase I clinical and thymidine replacement study (1997) (3)
Quantitation of beta-lapachone and 3-hydroxy-beta-lapachone in human plasma samples by reversed-phase high-performance liquid chromatography. (1997) (3)
Identification of an androgen-induced C3-P4 DNA binding protein in the cytosol of rat ventral prostate. (1993) (3)
Phase I clinical and pharmacokinetic (PK) trial of the kinesin spindle protein (KSP) inhibitor MK-0731 in patients with solid tumors (2007) (3)
Overview of advanced urothelial cancer trials of the Eastern Cooperative Oncology Group (2003) (3)
Phase II Study of 1-Hydroxyvitamin D 2 in the Treatment of Advanced Androgen-independent Prostate Cancer 1 (2003) (3)
55 A phase I study of SB-715992, a novel kinesin spindle protein (KSP) inhibitor: pharmacokinetic (PK)/pharmacodynamic (PD) modeling of absolute neutrophil counts (ANC) (2004) (3)
Phase II study of AT-101 to abrogate Bcl-2-mediated resistance to androgen-deprivation therapy (ADT) in patients (pts) with newly diagnosed androgen-dependent metastatic prostate cancer (ADMPC). (2011) (3)
Phase I study of sunitinib in combination with carboplatin (C) plus paclitaxel (P) in patients (pts) with advanced solid tumors (STs) (2008) (3)
Phase I study of docetaxel and topotecan in patients with advanced malignancies (2005) (3)
A phase dose finding trial of the intravenous injection of CV787, a prostate specific antigen-dependent cytolytic adenovirus in patients with advanced hormone refractory prostate cancer (HRPC) (2001) (2)
GENE EXPRESSION PROFILING FOR THE PREDICTION OF THERAPEUTIC RESPONSE TO ADJUVANT DOCETAXEL FOR HIGH RISK LOCALIZED PROSTATE CARCINOMA (2008) (2)
122 POSTER An inhibitor of acetyl polyamine oxidase specifically blocks androgen induced oxidative stress and prevents occurrence of prostate cancer in TRansgenic Adenocarcinoma of Mouse Prostate (TRAMP) (2006) (2)
Transforming Growth Facfors in Human Prostate Cancer (1991) (2)
Gemcitabine, Paclitaxel, and Piritrexim: A Phase I Study (2003) (2)
4520 POSTER Sunitinib plus interferon-alfa in the first-line treatment for metastatic renal cell carcinoma (mRCC): results of a dose-finding study (2007) (2)
4517 POSTER Sunitinib in patients with cytokine-refractory metastatic renal cell carcinoma (mRCC) (2007) (2)
Phase II evaluation of the sulfonylurea LY186,641 in men with hormone independent metastatic prostate cancer (1993) (2)
Enrollment of and toxicity in patients 70 years and older on CTEP/NCI-sponsored, single-agent phase I studies from 1980 to 2005. (2010) (2)
Assessment of adherence and relative dose intensity with oral chemotherapy in oncology clinical trials at an academic medical center (2018) (2)
Safety of long-term (LT) treatment (tmt) of chemotherapy (chemo)-naïve metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with abiraterone acetate plus prednisone (AA + P) for ≥ 4 years (yrs) (2016) (2)
Phase I Study of Piritrexim and Gemcitabine in Patients With Advanced Solid Tumors (2005) (2)
Abstract 4791: Metabolic switch from glycolysis to oxidative phosphorylation (ox-phos) provides survival advantage to anti-androgen-treated prostate cancer cells and make them vulnerable to mitochondrial metabolism inhibitors IACS-010759 and CB-839 (2020) (2)
Eligibility a nd R esponse G uidelines f or P hase I I C linical Trials i n A ndrogen-Indepen dent P rostate C ancer: Recommendations F rom t he P rostate-Specifi c A ntigen Working G roup (1999) (1)
A Phase Ib / II Trial of Granulocyte-Macrophage 2 Colony Stimulating Factor and Interleukin-2 for Renal Cell Carcinoma Patients with Pulmonary Metastases (2000) (1)
A Festschrift in Honor of Edward M. Messing, MD, FACS (2018) (1)
Metabolic Effects of Suramin(S) on Human Prostatic Cancer Cells (1990) (1)
First in human trial of the poly(ADP)-ribose polymerase inhibitor MK-4827 in patients with advanced cancer with antitumor activity in BRCA-deficient and sporadic ovarian cancers (2011) (1)
Prostate cancer clinical trials consortium: A multicenter mechanism for the rapid design, development, and implementation of early phase clinical trials. (2009) (1)
SUNITINIB MALATE (SU11248) – EFFICACY IN RENAL CELL CARCINOMA (RCC) (2006) (1)
Phase 2 Study of Weekly Paclitaxel Plus Estramustine in Metastatic Hormone‐Refractory Prostate Carcinoma: ECOG‐ACRIN Cancer Research Group (E1898) Trial (2017) (1)
Phase I trial of irofulven (MGI 114) plus docetaxel in advanced cancers (2005) (1)
352 Final Results of the First in Man Trial of MK4827, a Poly (ADP-ribose) Polymerase (PARP) Inhibitor with Antitumor Activity in BRCA Carriers and Sporadic Cancer Patients (2012) (1)
1589: Adjuvant Weekly Docetaxel for High-Risk Prostate Cancer Patients After Radical Prostatectomy (2005) (1)
A phase II trial of lapatinib (GW572016) in patients with recurrent prostate cancer as evident by a rising PSA (2008) (1)
A phase I trial of 5-fluorouracil, leucovorin, and dipyridamole given by concurrent 120-h continuous infusions (1992) (1)
Randomized phase II trial evaluating different schedules of zoledronic acid administration on bone mineral density in patients with stage D prostate cancer beginning androgen deprivation. (2011) (1)
362 POSTER A phase 2 trial of AP23573, an mTOR inhibitor, in patients (pts) with taxane-resistant androgen-independent prostate cancer (AIPC) (2006) (1)
A Novel Artificial Intelligence–Powered Method for Prediction of Early Recurrence of Prostate Cancer After Prostatectomy and Cancer Drivers (2022) (1)
Use of a DNA microfluorometric assay to measure proliferative response of mink lung cells to purified TGFβ and to TGFβ activity found in prostate cell conditioned medium (1995) (1)
448 Activation of a Specific Metabolic Pathway May Distinguish Aggressive From Indolent Prostate Cancer (2012) (1)
Terminal differentiation induction in LNCaP human prostate cancer cells (2004) (1)
Phase I study of oxaliplatin in combination with 5-fluorouracil (5-FU), leucovorin (LV) and capecitabine (ORAL FOLFOX-6) in patients with advanced or metastatic solid tumors (2005) (1)
A randomized phase II trial of mitoxantrone, estramustine and vinorelbine or 13-cis retinoic acid, interferon and paclitaxel in patients with metastatic hormone refractory prostate cancer: results of ECOG 3899 (2004) (1)
Novel antioxidant technology for prostate cancer chemoprevention and treatment (2006) (1)
A test of rats’ tolerance for 3β-acetoxyandrosta-1,5-dien-17-one ethylene ketal (ADEK), a new anti-androgen (2008) (1)
Abstract 2899: Mitophagy imparts enzalutamide resistance in prostate cancer (2015) (1)
Receptor-negative Prostate Cancer Cells Antiandrogen Hydroxyflutamide in Androgen Activation of Mitogen-activated Protein Kinase Pathway by the Updated (2002) (1)
Abstract B213: Pharmacokinetics (PK) and efficacy of axitinib in patients (pts) with sorafenib‐refractory metastatic renal cell carcinoma (mRCC) (2009) (0)
Evidence of an absorption phase after short intravenous suramin infusions (2004) (0)
A dose escalation trial of fixed dose gemcitabine and capecitabine. (2006) (0)
Abstract 4968: “Moonlighting Functions” of glycolytic enzymes relate to human prostate cancer invasion (2016) (0)
Abstract B091: Small-molecule inhibitors targeting a specific metabolic pathway for precision therapy of advanced castrate-resistant prostate cancer (2018) (0)
Randomized , Double-Blinded Phase II Evaluation of Docetaxel with or without Doxercalciferol in Patients withMetastatic , Androgen-Independent Prostate Cancer (2008) (0)
A plasmid DNA vaccine encoding prostatic acid phosphatase (PAP) elicits antigen-specific T cells in patients with stage D0 prostate cancer. (2006) (0)
A phase I study of MK-2206 in combination with lapatinib in patients (pts) with advanced solid tumors. (2013) (0)
Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma. (2023) (0)
Abstract 2165: Identification of a novel pathway of castrate resistant prostate cancer (CRPCa) growth (2011) (0)
Understanding Molecular Mechanisms of Androgen-Induced Oxidative Stress for Chemoprevention of Prostate Cancer (2005) (0)
The Inhibitory Effects of Growth Factors and Cytokines on Cell Proliferation (1993) (0)
Abstract 4630: Seminal AMACR protein: a non-invasive test in the detection of prostate cancer (2010) (0)
Future Prospects for the Treatment of Hormone-Responsive Tumors (1989) (0)
A phase I study of antisense Bcl-2 oligonucleotide (G3139) in combination with carboplatin (C) and paclitaxel (T) in patients with advanced solid tumors. (2006) (0)
Phase I and Pharmacokinetic Study of a Micronized Formulation of Carboxyamidotriazole , a Calcium Signal Transduction Inhibitor : Toxicity , Bioavailability and the Effect of Food 1 (2002) (0)
A PHASE IB STUDY OF GRANULOCYTE-MACROPHAGE COLONY STIMULATING FACTOR AND INTERLEUKIN-2: CLINICAL AND IMMUNOLOGICAL EFFECTS (1995) (0)
Predicting Response of Triple-Negative Breast Cancer to Neoadjuvant Chemotherapy Using a Deep Convolutional Neural Network-Based Artificial Intelligence Tool. (2023) (0)
Novel Inhibitors of Protein-Protein Interaction for Prostate Cancer Therapy (2014) (0)
Phase I Clinical and Pharmacokinetic Study of Perillyl Alcohol Administered Four Times a Day 1 (2000) (0)
TITLE: Novel Inhibitors of Protein-Protein Interaction for Prostate Cancer Therapy (2013) (0)
Phase I trial of perillyl alcohol administered (2003) (0)
Hereditary and sporadic cancers respond to niraparib (2013) (0)
Phase I Clinical Trial of Fazarabine as a Twenty-four-Hour Continuous Infusion1 (2006) (0)
Abstract 5408: AI powered-platform to predict gene modifications from prostate and breast cancer whole slide images (2023) (0)
TargetingAndrogenReceptorandJunDInteractionfor Preventionof Prostate Cancer Progression (2014) (0)
Antiangiogenic therapy for prostate cancer (2007) (0)
Protein kinase Cϵ associates with signal transducers and activators of transcription 3, which is constitutively activated during induction and progression of prostate cancer (2007) (0)
First in Human Trial of MK4827, a Poly(ADP)ribose Polymerase (PARP) Inhibitor With Antitumor Activity in BRCA Mutation Carrier and Sporadic Cancer Patients (2013) (0)
A phase I study of R-(-)-gossypol (AT-101) in combination with cisplatin (P) and etoposide (E) in patients (pts) with advanced solid tumors and extensive-stage small cell lung cancer (ES-SCLC). (2011) (0)
Phase I pharmacodynamic trial of sequential sunitinib (SU) with bevacizumab (bev) in patients with renal cell carcinoma (mRCC) and other advanced solid malignancies. (2011) (0)
Activation of Mitogen-activated Protein Kinase Pathway by the Antiandrogen Hydroxyflutamide in Androgen Receptor-negative Prostate Cancer Cells 1 (2002) (0)
Prostate Cancer Marc S. Ernstoff, John A. Heaney, Richard E. Peschel, eds. Malden (MA): Blackwell Science, Inc., 1998. 211 pp., illus. $75. ISBN 0-6320-43172 (1998) (0)
Phase I Clinical Trial of Fazarabine as a Twenty-four-Hour Continuous Infusion 1 (2006) (0)
Abstract 2357: Inhibition of CDK8/19 mediator kinase suppresses primary and metastatic growth of castration-resistant prostate cancer (2022) (0)
Use of zoledronic acid (ZA) and interleukin-2 (IL-2) to activate and expand Vγ9Vδ2 T cells for therapeutic use in patients with metastatic renal cell carcinoma (mRCC). (2006) (0)
Phase I P harmacokinetic a nd P harmacodynamic S tudy o f Recombinant H uman E ndostatin i n P atients W ith A dvanced Solid T umors (2003) (0)
Role of JunD in androgen induction of oxidative stress in androgen-dependent human prostate cancer cells and in mouse prostate (2007) (0)
APhase I Pharmacokinetic and Pharmacodynamic Correlative Study of theAntisense Bcl-2 Oligonucleotide G 3139 , in Combinationwith Carboplatin and Paclitaxel , in Patients with Advanced Solid Tumors (2008) (0)
Testicular and Penile CancerMarc S. Ernstoff, John A. Heaney, Richard E. Peschel, eds. Malden (MA): Blackwell Science, Inc., 1998. 173 pp., illus. $85. ISBN 0-63204-319-9 (1998) (0)
Pharmacokinetic and Pharmacodynamic Correlative Study of theAntisense Bcl-2 Oligonucleotide G 3139 , in Combinationwith Carboplatin and Paclitaxel , in Patients with Advanced Solid Tumors (2008) (0)
Abstract 2583: Targeting a novel pathway for prostate cancer therapy (2011) (0)
Cancer Therapy : Clinical Phase II Study of Dasatinib in Patients with Metastatic Castration-Resistant Prostate Cancer (2009) (0)
Phase I evaluation of 773U82-HCl in a two-hour infusion repeated daily for three days (1992) (0)
Fibrosis without an Antitumor Effect in Nude Mice 1 Induces Cachexia and Systemic β Transforming Growth Factor (2006) (0)
Abstract 2844: Inhibiting androgen receptor and JunD protein interaction to prevent prostate cancer progression (2012) (0)
Cytochrome P450 interacting medication use in adult advanced solid tumor and phase I trial patients. (2014) (0)
The influence of body mass index (BMI) on outcome in patients with advanced germ cell tumors (GCT). (2006) (0)
Abstract 4396: Evaluation of gene expression and transcriptional activation in patients treated with vorinostat: (2011) (0)
Autophagosomal Sequestration of Mitochondria as an Indicator of Antiandrogen Therapy Resistance of Prostate Cancer (PCa) (2017) (0)
Clinical and Immunological Effects of Granulocyte-Macrophage Colony-stimulating Factor Coadministered with Interleukin 2: A Phase IB Study 1 (2008) (0)
1453: The Induction of Cellular Senescence During Therapy for Advanced Prostate Cancer (2004) (0)
Denmeade Endothelial Cell Prodrug for Cancer Therapy Activated Tumor − Engineering a Prostate-Specific Membrane Antigen (2012) (0)
A phase I study of the gamma-secretase inhibitor RO4929097 and capecitabine in refractory solid tumors. (2012) (0)
Phase I Clinical and Pharmacokinetic Study of NSC 655649 , a Rebeccamycin Analogue , Given in Both Single-Dose and Multiple-Dose Formats 1 (2002) (0)
WE-C-BRC-05: Use of FLT PET Imaging to Assess Tyrosine Kinase Inhibitor (TKI) Treatment Response (2009) (0)
A phase I study to determine the maximum tolerated dose and safety of oral LR-103 (1α,24(S)Dihydroxyvitamin D2) in patients with advanced cancer (2015) (0)
Phase I T rial o f I ntravenous T hymidine a nd C arboplatin in P atients W ith A dvanced C ancer (1999) (0)
Randomized phase II trial of docetaxel, with or without doxercalciferol, in advanced, androgen-independent prostate cancer (2007) (0)
Abstract 3846: A metabolic pathway targeted inhibitor for precision therapy of castrate-resistant prostate cancer (2018) (0)
Phase I II S tudy o f I nterferon A lfa-NL a s A djuvant T reatment for R esectable R enal C ell C arcinoma: A n E astern C ooperative Oncology G roup/Intergroup T rial (2003) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With George Wilding?

George Wilding is affiliated with the following schools:

George Wilding's Academic­Influence.com Rankings